$AXSM News

Here’s How Much You Would Have Made Owning Axsome Therapeutics Stock In The Last 5 Years

If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today

Mizuho Maintains Outperform on Axsome Therapeutics, Raises Price Target to $316

Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition

Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $251

RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $297

Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results

Guggenheim Maintains Buy on Axsome Therapeutics, Raises Price Target to $275

Wells Fargo Maintains Overweight on Axsome Therapeutics, Raises Price Target to $256

Needham Maintains Buy on Axsome Therapeutics, Raises Price Target to $268

Axsome Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation

Axsome Therapeutics, Inc. (AXSM) Q2 2026 Earnings Call Transcript

Axsome Therapeutics Q2 EPS $(0.99) Misses $(0.83) Estimate, Sales $218.400M Miss $221.230M Estimate

Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $306

BMO Capital Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $310

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target

Axsome Therapeutics Says FDA Accepts NDA For AXS-12 For Treatment Of Cataplexy In Narcolepsy; PDUFA Target Action Date Set May 1, 2027

HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target

RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $304

Axsome Therapeutics Doses First Patient In FOCUS-2 Phase 3 Trial Of Solriamfetol For Children With Attention Deficit Hyperactivity Disorder